

Investor Relations Brief

4

2026

April



Molecular Diagnostics: CE-IVDR Class D & Class B Certification



Bioneer Chairman Han-Oh Park (3rd from left) & Diagnostics Division President Jae-Bong Ko (2nd from left)



High-Throughput Molecular Diagnostic System:
ExiStation™ FA 96



HIV-1 Quant Assay Kit: AccuPower® HIV-1
Quant Kit (ExiStation™ FA 96)



Point-of-Care Molecular Diagnostic Device:
IRON-qPCR™



RV Multiplex Rapid Kit: AccuPower®
qRV Kit (IRON-qPCR™)

Molecular Diagnostics: CE-IVDR Class D & Class B Certification

On March 9, Bioneer obtained European CE-IVDR certification for two diagnostic kits, including a high-throughput HIV-1 quantitative kit used with its next-generation, fully automated molecular diagnostic system, ExiStation™ FA 96. The certifications mark an important step toward expanding Bioneer's molecular diagnostics business into global markets.

1. HIV-1 Quantitative Kit

Bioneer's HIV-1 quantitative diagnostic kit for use with ExiStation™ FA 96 received CE-IVDR Class D certification, the highest risk class under the EU's in-vitro diagnostic framework, clearing the way for its launch in global markets.

The transition from the EU's former IVDD framework to IVDR has significantly tightened regulatory requirements, particularly for Class D diagnostics targeting high-risk pathogens such as HIV, HBV, and HCV. Bioneer developed three quantitative kits for this category and was selected for approximately KRW 5 billion in clinical research funding through Korea's Ministry of Trade, Industry and Energy's Medical Device R&D Program. The company subsequently completed four years of clinical trials in France to obtain certification, strengthening its qualifications for participation in global public procurement markets, including Europe.

The HIV-1 quantitative test is generally performed twice a year using patients' blood samples to monitor viral load and help healthcare providers assess treatment response and determine whether treatment adjustments may be necessary. Because the test requires highly sensitive technology to quantify residual virus even at very low levels following treatment, development is technically demanding and the market is served by a relatively limited number of major diagnostic companies.

According to the World Health Organization (WHO), an estimated 40.8 million people were living with HIV globally, with approximately 1.3 million new infections and 630,000 HIV-related deaths reported in 2024. Global health organizations are working to increase viral suppression rates toward 95%, supporting continued demand for quantitative HIV testing. The global market for HIV diagnostic testing was valued at approximately \$6.7095 billion in 2026 and is projected to grow at a compound annual growth rate of 8.9%, according to Future Market Insights.

Bioneer's HIV-1 high-throughput quantitative kit also features a rapid turnaround time and can be distributed at room temperature, eliminating the need for cold-chain shipping. This can help reduce logistics costs and support more reliable supply in regions with limited healthcare infrastructure.

ExiStation™ FA 96 is a next-generation molecular diagnostic system developed over seven years to address limitations in high-throughput molecular testing highlighted during the COVID-19 pandemic. The system automates the entire testing process, from sample-tube opening and closing to nucleic acid extraction and real-time PCR analysis and can process up to 96 tests within two hours. Automated opening and closing of sample tubes within the instrument also helps reduce potential exposure risks while streamlining the testing process.

Quantitative hepatitis B and C kits for use with the platform are currently undergoing certification. ExiStation™ FA 96 was also recognized as one of the Top 10 Innovative Medical Devices under Korea's Medical Device R&D Program.

With the CE-IVDR certification, Bioneer expects to expand its presence in the global infectious-disease diagnostics market and pursue opportunities in public procurement and other institutional markets.

Molecular Diagnostics: CE-IVDR Class D & Class B Certification

2. Two Respiratory Virus (RV) Multiplex Diagnostic Kits

Bioneer also obtained CE-IVDR Class B certification for two respiratory virus (RV) multiplex diagnostic kits, completing the certification of high-throughput and point-of-care (POC) kits designed to support responses to future respiratory virus outbreaks. The two kits are used with the CE-IVDR-certified ExiStation™ FA 96 and IRON-qPCR™ platforms, respectively, and simultaneously detect COVID-19, influenza A/B, and RSV A/B.

The global respiratory molecular diagnostics market is estimated at approximately \$7 billion in 2026, with estimates varying slightly by research firm, and is projected to grow at an average annual rate of 6.5%.

The ExiStation™ FA 96 kit can process 94 tests within two hours through a fully automated workflow without requiring a negative-pressure room. Conventional molecular diagnostic workflows often require manual opening of individual sample tubes, increasing potential exposure risks for testing personnel. For large-scale testing, additional infection-control measures, including negative-pressure rooms and full personal protective equipment, may also be required, potentially extending testing times beyond four hours while increasing staff fatigue and single-use consumables.

In contrast, ExiStation™ FA 96 automatically opens, dispenses, and reseals sample tubes within the instrument, with an integrated sterilization chamber, before ejecting the tubes. This automated workflow enables up to 94 tests to be processed within two hours while reducing manual handling and simplifying large-scale testing operations.

The IRON-qPCR™ kit enables simultaneous point-of-care detection of five respiratory viruses, including COVID-19. Once a sample is loaded, the system automatically performs nucleic acid extraction and real-time PCR, delivering results for COVID-19, influenza A/B, and RSV A/B within 40 minutes.

With CE-IVDR certification for both respiratory virus kits, Bioneer has strengthened its diagnostic portfolio for future respiratory virus outbreaks. If a novel respiratory virus emerges, Bioneer plans to develop a corresponding detection reagent within two weeks and incorporate it into these platforms, enabling simultaneous testing for existing and newly emerging viruses. By offering both high-throughput and point-of-care diagnostic solutions, Bioneer aims to strengthen pandemic preparedness in Korea and global markets.

Bioneer is also expanding beyond diagnostics into therapeutic development. The company is advancing its influenza A therapeutic program, which was selected in 2025 as an innovative challenge-based pandemic response project by Korea's Ministry of Health and Welfare. Bioneer plans to continue expanding its therapeutic development programs across respiratory viruses, with the goal of connecting diagnostic results with targeted antiviral treatment strategies and contributing to improved patient outcomes.

CosmeRNA: MOU with Korea Hairdressers Association

Bioneer has signed a strategic memorandum of understanding (MOU) with the Korea Hairdressers Association to collaborate on scalp and hair-loss care. The partnership aims to increase awareness of CosmeRNA SalonPro and expand its presence in professional salon channels, while responding to growing demand for scalp and hair-loss care and promoting science-based scalp-care solutions.

The signing ceremony was held on the 11th at the Daejeon Convention Center during the 2026 OMC Asia Cup and Inter Beauty Fair. The Korea Hairdressers Association is one of Korea's largest beauty industry organizations, with approximately 86,000 members and 186 chapters nationwide. Bioneer plans to leverage the Association's nationwide network to introduce its CosmeRNA scalp-care program through salon channels and expand scalp-care services in collaboration with beauty professionals.

The two organizations plan to develop training programs for hairdressers, promote salon-based scalp-care services, and conduct joint activities to raise awareness of scalp health. By connecting professional training with salon business opportunities, the partnership will promote a standardized scalp-care program that can be implemented in salons. The organizations also plan to cooperate on OMC Asia Cup sponsorship, as well as annual advertising and training programs.

At the event, Bioneer presented a plaque and trophy to the chair of the Association's scalp-care committee in recognition of contributions to the beauty industry.

A Bioneer official said, "This partnership marks an important step toward establishing CosmeRNA SalonPro in the professional salon channel. We will continue working with beauty professionals to expand access to science-based scalp-care solutions."




AceBiome: Exhibits at NPEW 2026 Natural Products Expo

AceBiome exhibited at Natural Products Expo West (NPEW) 2026 in Anaheim, California, showcasing its product portfolio to global distribution and retail professionals. NPEW is one of North America's leading trade shows for dietary supplements, natural foods, and organic lifestyle products, attracting industry professionals from around the world.

The company showcased its weight-management probiotic brand BNRThin, women's health product BNR Queen, and joint-health product AnaParactin, presenting a health portfolio spanning weight management, gut health, and joint health across different stages of life. AceBiome also introduced its North American market entry strategy, centered on BNRThin S30, a product developed specifically for the U.S. market.

During the show, AceBiome held meetings with global distributors and retail partners to explore potential collaborations and business opportunities in North America. The company also used the event to gain firsthand insights into consumer trends and market demand, while continuing to expand its global business network and establish partnerships for future market growth.



Business Updates

AceBiome: AnaParactin Patch Launch, Seoul Marathon Sponsor

AceBiome has launched the AnaParactin Patch, a new addition to its joint-care brand AnaParactin, exclusively through Shinsegae Live Shopping. Following Joint AnaParactin and AnaParactin Balm, the patch is the brand's first “apply-and-wear” product, completing a portfolio built around ParActin, an ingredient derived from *Tinospora cordifolia* extract, across “take, apply, and wear” formats.

The patch combines a cooling menthol sensation with stretchable sports fabric designed to conform to high-movement areas such as the knees, shoulders, elbows, and lower back. Its patented TPE gel and breathable structure are designed to support comfortable wear while delivering the product's active ingredients, extending AnaParactin's ParActin-based joint-care offering into a convenient, wearable format.

Alongside the product launch, AceBiome served as an official sponsor of the 2026 Seoul Marathon (Dong-A Marathon), operating a brand experience program in connection with the event. The company distributed AnaParactin Patches to approximately 40,000 Seoul Marathon participants and showcased its full product lineup — Joint AnaParactin, AnaParactin Balm, and AnaParactin Patch — at the running expo.

By pairing the new product launch with a major sporting event, AceBiome created additional opportunities for consumers to experience its joint-care products in active, running-focused settings, while expanding brand awareness in the joint-health category.



Business Updates

AceBiome Wins 2026 KCAB Best Brand Awards

AceBiome's flagship brands BNRThin, BNR Queen, and Joint AnaParactin were named winners in the diet probiotics, menopause probiotics, and joint health supplement categories, respectively, in the Korea Consumer Assessment Board's (KCAB) "2026 Best Brands as Rated by Korean Consumers."

The evaluation combines public market research, data from relevant institutions, and consumer satisfaction reviews and complaint data to assess brand competitiveness. The recognition highlights AceBiome's expanding product portfolio, which addresses diverse health needs across weight management, gut health, women's life-stage health, and joint care.


AceBiome's flagship brand BNRThin is a weight-management probiotic based on the BNR17 strain. The brand has recorded cumulative sales of KRW 1 trillion and 20 million units sold. BNR Queen combines the BNR17 probiotic with Sophora japonica fruit extract and vitamins D and A, zinc, and selenium, targeting women's health during menopause. Joint AnaParactin, meanwhile, is formulated with ParActin, derived from *Tinospora cordifolia* extract, along with vitamins K2 and D3 to support joint and bone health.

With this recognition, AceBiome is expanding its brand portfolio across weight management, gut health, women's health, and joint and bone health. The company plans to continue strengthening consumer trust through research into functional ingredients and the development of products tailored to specific health needs.



Business Updates

Bioneer: 34th AGM Concludes, Advancing a Focused Strategy



Bioneer held its 34th Annual General Meeting of Shareholders on March 31 at its Daejeon Global Center. All key agenda items were approved by shareholders, including the appointment of new and returning directors, resulting in a strengthened board structure and enhanced financial management capabilities.

1. Board Composition Finalized, Governance Strengthened

Chairman Han-Oh Park was reappointed as an inside director for a new three-year term, receiving 78.0% approval of the voting shares. Park founded Bioneer in 1992 and has led the company for more than three decades, overseeing its growth alongside the development of Korea's biotechnology industry. His reappointment provides continuity in the company's management and long-term business strategy.

CFO Young-Seok Kim was newly appointed as an inside director. A certified public accountant, Kim has been responsible for strengthening Bioneer's financial management and performance management since joining the company. In his new role, he will support efforts to further strengthen Bioneer's finance and investor relations functions, with a focus on communication with shareholders and capital-market participants in Korea and overseas.

Dr. Byung-Gun Lee was newly appointed as an outside director. Dr. Lee has held leadership positions at major Korean pharmaceutical and biotechnology companies and has built a global professional network. He will contribute his industry experience and expertise to Bioneer's drug development and commercialization strategies.

Business Updates

Bioneer: 34th AGM Concludes, Advancing a Focused Strategy

2. Eliminating Accumulated Deficit, Restructuring Financial Position

Shareholders also approved, with 92.1% support, a proposal to offset the accumulated deficit using approximately KRW 150 billion in capital reserves. The measure fully eliminated the company's accumulated deficit and established a financial structure that could support future shareholder returns, including dividends and share buybacks, as the company's long-term investments begin to generate sustained profits.

3. Sharing Business Status and Future Vision with Shareholders

Chairman Han-Oh Park personally chaired the meeting, which began at 10:30 a.m. Following the approval of all key agenda items, Park spent approximately one hour presenting the company's current business status and future plans directly to shareholders, followed by a Q&A session that continued past 1 p.m.

Over the course of approximately two and a half hours, Park discussed the company's business progress and responded to shareholder questions. The 34th Annual General Meeting provided an opportunity for shareholders to exchange views with management and gain a deeper understanding of the company's business strategy and future direction. The business presentation materials have been posted on the company's IR website for shareholders who were unable to attend the meeting.

Following the restructuring of its board and financial position through the AGM, Bioneer plans to strengthen execution across its business units. The Diagnostics Division is pursuing opportunities in global public procurement markets, while the drug development team continues to advance the Phase 1b clinical trial of SRN-001. Bioneer also plans to expand AceBiome and CosmeRNA in overseas markets, while building patent-protected product portfolios and strengthening their sales foundations to support sustainable growth amid a changing business environment.

Bioneer will continue to enhance corporate value through business performance and pursue long-term growth based on continued communication and trust with its shareholders.